Ibio Inc (IBIO)

$1.81 -0.11 (-5.73%)
Market Cap 69.40M
Revenue (ttm) 400,000.00
Net Income (ttm) -18.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,595.00%
Debt to Equity Ratio 0.01
Volume 1,266,800
Avg Vol 985,402
Day's Range N/A - N/A
Shares Out 36.14M
Stochastic %K 14%
Beta 1.36
Analysts Strong Sell
Price Target $5.46

Company Profile

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies agai...

Industry: Biotechnology
Sector: Healthcare
Phone: 979 446 0027
Website: ibioinc.com
Address:
11750 Sorrento Valley Road, Suite 200, San Diego, United States
Schube1255
Schube1255 Apr. 24 at 12:02 PM
$IBIO you cant fix stupid, $IBIO will drop to 1$ then R/S , they needed funds for their yachts so they upped the price and you bought in - will happen again and again
1 · Reply
suredubb
suredubb Apr. 24 at 3:49 AM
$IBIO CEO, CFO and Chief Legal Officer all bought shares last month between $1.70 and $2.00 a share 49% insider owned loading zone… smart money and insiders love IBIO at these prices
0 · Reply
StillTippin44
StillTippin44 Apr. 24 at 2:24 AM
$IBIO same shit every day every month and every year lol if you arent shorting this you arent making money. thats coming from a stupid long position.
0 · Reply
Rower5oh
Rower5oh Apr. 23 at 9:34 PM
$IBIO I think the anchor of dilution is dragging us down at the moment. I’ll be following the O/S count closely. How about a f@&king partnership, Martin? Let’s let one of the Big Boys fund this instead of shareholders. FFS
0 · Reply
FkDisManipulation
FkDisManipulation Apr. 23 at 7:49 PM
$IBIO opened minor position 1.80
0 · Reply
BixbyKnolls
BixbyKnolls Apr. 23 at 6:18 PM
$IBRX While the $LABU $XBI struggle- ImmunityBio - back green! $IBIO so undervalued - all systems go!
0 · Reply
suredubb
suredubb Apr. 23 at 6:13 PM
$IBIO this action destroys retail… hopefully close to bottom, and dip before the rip
1 · Reply
Retail_Lives_Matter
Retail_Lives_Matter Apr. 23 at 3:04 PM
$IBIO
0 · Reply
DrMash
DrMash Apr. 22 at 8:56 AM
$IBIO : looking is ready for the next leg up After the recent consolidation around the $1.90–$2.00 zone, price is holding strong and building a clean base. The dip got bought, volume is stabilizing, and momentum looks like it’s resetting for a push. With the move to Nasdaq Capital Market attracting more eyes and liquidity, this could be the catalyst for continuation. Key levels: - Support: $1.85–$1.90 - Breakout zone: $2.10–$2.20 - Target: $2.60 by April 30 🚀 If bulls step in with volume, this can move fast. Watching for a clean break above $2.20 to confirm strength.
2 · Reply
suredubb
suredubb Apr. 22 at 7:37 AM
$IBIO this stock going to blow when we start getting early clinical updates from Australia.. IBIO has cash until 2028 Currently at a 20% discount to what institutions just paid in january at $2.35 a share loading zone for smart money.. good time to take a position
1 · Reply
Latest News on IBIO
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

Apr 8, 2026, 7:00 AM EDT - 16 days ago

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Mar 16, 2026, 4:30 PM EDT - 5 weeks ago

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

Mar 9, 2026, 7:00 AM EDT - 6 weeks ago

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

iBio to Participate in Upcoming Investor Conferences

Feb 24, 2026, 7:00 AM EST - 2 months ago

iBio to Participate in Upcoming Investor Conferences

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

Feb 10, 2026, 4:05 PM EST - 2 months ago

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio Announces $26 Million Private Placement

Jan 9, 2026, 7:00 AM EST - 3 months ago

iBio Announces $26 Million Private Placement

iBio to Participate in the 8th Annual Evercore Healthcare Conference

Nov 24, 2025, 4:15 PM EST - 5 months ago

iBio to Participate in the 8th Annual Evercore Healthcare Conference

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:01 PM EST - 5 months ago

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

Oct 30, 2025, 7:00 AM EDT - 6 months ago

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 23, 2025, 7:00 AM EDT - 6 months ago

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

Oct 21, 2025, 7:00 AM EDT - 6 months ago

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Sep 5, 2025, 7:30 AM EDT - 8 months ago

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

iBio Announces Closing of $50 Million Public Offering

Aug 25, 2025, 7:00 AM EDT - 8 months ago

iBio Announces Closing of $50 Million Public Offering

iBio Announces Pricing of $50 Million Public Offering

Aug 19, 2025, 8:01 AM EDT - 8 months ago

iBio Announces Pricing of $50 Million Public Offering

iBio Announces Proposed Public Offering

Aug 18, 2025, 4:01 PM EDT - 8 months ago

iBio Announces Proposed Public Offering

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Jun 24, 2025, 7:00 AM EDT - 10 months ago

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

Jun 23, 2025, 4:15 PM EDT - 10 months ago

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

Jun 16, 2025, 7:00 AM EDT - 11 months ago

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

May 5, 2025, 8:00 AM EDT - 1 year ago

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

iBio Reports Fiscal Third Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 1 year ago

iBio Reports Fiscal Third Quarter 2025 Financial Results

iBio Raises $6.2 Million Through Warrant Inducement Transaction

Apr 29, 2025, 1:43 PM EDT - 1 year ago

iBio Raises $6.2 Million Through Warrant Inducement Transaction

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

Apr 22, 2025, 8:00 AM EDT - 1 year ago

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Apr 7, 2025, 7:00 AM EDT - 1 year ago

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

iBio to Begin Trading on the Nasdaq Stock Exchange

Feb 19, 2025, 4:05 PM EST - 1 year ago

iBio to Begin Trading on the Nasdaq Stock Exchange

iBio Reports Fiscal Second Quarter 2025 Financial Results

Feb 10, 2025, 4:05 PM EST - 1 year ago

iBio Reports Fiscal Second Quarter 2025 Financial Results

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

Jan 2, 2025, 7:00 AM EST - 1 year ago

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

iBio Reports Fiscal First Quarter 2025 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

iBio Reports Fiscal First Quarter 2025 Financial Results

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sep 20, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

Aug 12, 2024, 4:30 PM EDT - 1 year ago

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

iBio Closes Sale of Manufacturing Facility in Texas

Jun 3, 2024, 7:00 AM EDT - 2 years ago

iBio Closes Sale of Manufacturing Facility in Texas

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 4:05 PM EDT - 2 years ago

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

iBio stock nearly tripled on Wednesday: here's why

Mar 27, 2024, 2:43 PM EDT - 2 years ago

iBio stock nearly tripled on Wednesday: here's why

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Mar 27, 2024, 7:00 AM EDT - 2 years ago

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

iBio Announces $15.0 Million Private Placement

Mar 26, 2024, 7:35 PM EDT - 2 years ago

iBio Announces $15.0 Million Private Placement

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

Feb 26, 2024, 7:45 AM EST - 2 years ago

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

iBio Announces Participation in 23rd Annual PepTalk Conference

Jan 16, 2024, 8:15 AM EST - 2 years ago

iBio Announces Participation in 23rd Annual PepTalk Conference

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

Jan 16, 2024, 6:50 AM EST - 2 years ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR GRI VYNE

iBio Amends and Extends Maturity of Credit Agreement

Dec 26, 2023, 7:15 AM EST - 2 years ago

iBio Amends and Extends Maturity of Credit Agreement

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

Dec 5, 2023, 8:00 AM EST - 2 years ago

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

iBio Announces Reverse Stock Split

Nov 27, 2023, 5:20 PM EST - 2 years ago

iBio Announces Reverse Stock Split

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

Nov 1, 2023, 8:24 AM EDT - 2 years ago

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

iBio Explains Recent Filing of Registration Statement

Oct 2, 2023, 6:45 AM EDT - 2 years ago

iBio Explains Recent Filing of Registration Statement

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

Sep 27, 2023, 4:19 PM EDT - 2 years ago

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

iBio Announces Amendment to Credit Agreement with Woodforest

Sep 21, 2023, 4:05 PM EDT - 2 years ago

iBio Announces Amendment to Credit Agreement with Woodforest

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

Aug 14, 2023, 4:15 PM EDT - 2 years ago

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

Jun 27, 2023, 8:00 AM EDT - 3 years ago

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

iBio Forges Research Collaboration with the National Institutes of Health

Jun 12, 2023, 4:15 PM EDT - 3 years ago

iBio Forges Research Collaboration with the National Institutes of Health

iBio to Participate in the JMP Securities Life Sciences Conference

May 9, 2023, 4:30 PM EDT - 3 years ago

iBio to Participate in the JMP Securities Life Sciences Conference

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

Apr 4, 2023, 4:05 PM EDT - 3 years ago

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

Mar 31, 2023, 8:10 AM EDT - 3 years ago

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

Schube1255
Schube1255 Apr. 24 at 12:02 PM
$IBIO you cant fix stupid, $IBIO will drop to 1$ then R/S , they needed funds for their yachts so they upped the price and you bought in - will happen again and again
1 · Reply
suredubb
suredubb Apr. 24 at 3:49 AM
$IBIO CEO, CFO and Chief Legal Officer all bought shares last month between $1.70 and $2.00 a share 49% insider owned loading zone… smart money and insiders love IBIO at these prices
0 · Reply
StillTippin44
StillTippin44 Apr. 24 at 2:24 AM
$IBIO same shit every day every month and every year lol if you arent shorting this you arent making money. thats coming from a stupid long position.
0 · Reply
Rower5oh
Rower5oh Apr. 23 at 9:34 PM
$IBIO I think the anchor of dilution is dragging us down at the moment. I’ll be following the O/S count closely. How about a f@&king partnership, Martin? Let’s let one of the Big Boys fund this instead of shareholders. FFS
0 · Reply
FkDisManipulation
FkDisManipulation Apr. 23 at 7:49 PM
$IBIO opened minor position 1.80
0 · Reply
BixbyKnolls
BixbyKnolls Apr. 23 at 6:18 PM
$IBRX While the $LABU $XBI struggle- ImmunityBio - back green! $IBIO so undervalued - all systems go!
0 · Reply
suredubb
suredubb Apr. 23 at 6:13 PM
$IBIO this action destroys retail… hopefully close to bottom, and dip before the rip
1 · Reply
Retail_Lives_Matter
Retail_Lives_Matter Apr. 23 at 3:04 PM
$IBIO
0 · Reply
DrMash
DrMash Apr. 22 at 8:56 AM
$IBIO : looking is ready for the next leg up After the recent consolidation around the $1.90–$2.00 zone, price is holding strong and building a clean base. The dip got bought, volume is stabilizing, and momentum looks like it’s resetting for a push. With the move to Nasdaq Capital Market attracting more eyes and liquidity, this could be the catalyst for continuation. Key levels: - Support: $1.85–$1.90 - Breakout zone: $2.10–$2.20 - Target: $2.60 by April 30 🚀 If bulls step in with volume, this can move fast. Watching for a clean break above $2.20 to confirm strength.
2 · Reply
suredubb
suredubb Apr. 22 at 7:37 AM
$IBIO this stock going to blow when we start getting early clinical updates from Australia.. IBIO has cash until 2028 Currently at a 20% discount to what institutions just paid in january at $2.35 a share loading zone for smart money.. good time to take a position
1 · Reply
Retail_Lives_Matter
Retail_Lives_Matter Apr. 21 at 11:09 PM
$IBIO cmon iBio, MAGA!!!!!
0 · Reply
Rower5oh
Rower5oh Apr. 21 at 10:06 PM
$IBIO O/S share count is 36.1M. Was 34.5M last week.
1 · Reply
skitime
skitime Apr. 21 at 7:13 PM
$IBIO Dang!
0 · Reply
biowatcher
biowatcher Apr. 21 at 6:48 PM
$IBIO
0 · Reply
Joelew22
Joelew22 Apr. 21 at 1:34 PM
$IBIO
1 · Reply
SpaceRunners
SpaceRunners Apr. 20 at 10:51 PM
$NNE $IBIO $MDAI $GXAI AI
0 · Reply
suredubb
suredubb Apr. 20 at 9:54 PM
$IBIO smart money loves IBIO in these low ranges.. you don’t want to miss their big buying days loading zone.. good time to scale in
2 · Reply
suredubb
suredubb Apr. 20 at 3:41 PM
$IBIO on sale… great time to scale in
1 · Reply
Retail_Lives_Matter
Retail_Lives_Matter Apr. 20 at 2:51 PM
$IBIO POFS
0 · Reply
Rondio
Rondio Apr. 18 at 12:49 AM
$IBIO dilution with 11 mil warrants that’ll be converted by May 20th hope here is that its absorbed quickly lol
0 · Reply
Retail_Lives_Matter
Retail_Lives_Matter Apr. 17 at 10:19 PM
$IBIO you’re welcome https://youtu.be/Jprla2NvHY0?si=Tp7i80c09Zwjx_0t
3 · Reply
focafoca99
focafoca99 Apr. 17 at 9:50 PM
$IBIO amended a prior 8-K to correct the Series G warrant expiry date to May 20, 2026 and updated disclosure on outstanding warrants and share counts. https://www.rapidticker.com/news/ibio-sec-filing-8dd20d
0 · Reply